Evidence mapPaperPMID 36733464Full record

ReviewBreast cancer (Dove Medical Press)2023

Breast Cancer Management in the Era of Covid-19; Key Issues, Contemporary Strategies, and Future Implications.

A H M Safayet Ullah Prodhan, Dewan Zubaer Islam, Shahad Saif Khandker, Mohd Raeed Jamiruddin, Adnan Abdullah, Brian Godman, Sylvia Opanga, Santosh Kumar, Paras Sharma, Nihad Adnan and 2 more

Abstract readReview
In one paragraph

Review in Breast cancer (Dove Medical Press), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

A H M Safayet Ullah ProdhanDepartment of Biochemistry and Molecular Biology, Jahangirnagar University, Dhaka, 1342, Bangladesh.ORCID 0000-0002-9451-2669
Dewan Zubaer IslamDepartment of Microbiology, Jahangirnagar University, Dhaka, 1342, Bangladesh.ORCID 0000-0003-0023-1733
Shahad Saif KhandkerDepartment of Biochemistry, Gonoshasthaya Samaj Vittik Medical College, Dhaka, 1344, Bangladesh.ORCID 0000-0003-4724-0645
Mohd Raeed JamiruddinDepartment of Pharmacy, BRAC University, Dhaka, 1212, Bangladesh.ORCID 0000-0003-0495-4808
Adnan AbdullahUnit of Occupational Medicine, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia, (National Defence University of Malaysia), Kuala Lumpur, 57000, Malaysia.ORCID 0000-0003-4323-7617
Brian GodmanDepartment of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.ORCID 0000-0001-6539-6972
Sylvia OpangaDepartment of Pharmacy, University of Nairobi, Nairobi, Kenya.
Santosh KumarDepartment of Periodontology and Implantology, Karnavati School of Dentistry, Karnavati University, Gandhinagar, Gujarat, India.ORCID 0000-0002-5117-7872
Paras SharmaDepartment of Pharmacognosy, BVM College of Pharmacy, Gwalior, Madhya Pradesh, 474006, India.ORCID 0000-0003-0107-2666
Nihad AdnanDepartment of Microbiology, Jahangirnagar University, Dhaka, 1342, Bangladesh.ORCID 0000-0002-4999-4793
Alice PisanaDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Mainul HaqueThe Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan, Nasional Malaysia (National Defence University of Malaysia), Kuala Lumpur, 57000, Malaysia.ORCID 0000-0002-6124-7993

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the COVID-19 pandemic, several priority diseases were not getting sufficient attention. Whilst breast cancer is a fatal disease affecting millions worldwide, identification and management of these patients did not initially attract critical attention to minimize the impact of lockdown, post-lockdown, and other measures. Breast cancer patients' conditions may not remain stable without proper care, worsening their prognosis. Proper care includes the timely instigation of surgery, systemic therapy, and psychological support. This includes low-and middle-income countries where there are already concerns with available personnel and medicines to adequately identify and treat these patients. Consequently, there was a need to summarize the current scenario regarding managing breast cancer care during COVID-19 across all countries, including any guidelines developed. We systematically searched three scientific databases and found 76 eligible articles covering the medical strategies of high-income countries versus LMICs. Typically, diagnostic facilities in hospitals were affected at the beginning of the pandemic following the lockdown and other measures. This resulted in more advanced-stage cancers being detected at initial presentation across countries, negatively impacting patient outcomes. Other than increased telemedicine, instigating neo-adjuvant endocrine therapy more often, reducing non-essential visits, and increasing the application of neo-adjuvant chemotherapy to meet the challenges, encouragingly, there was no other significant difference among patients in high-income versus LMICs. Numerous guidelines regarding patient management evolved during the pandemic to address the challenges posed by lockdowns and other measures, which were subsequently adopted by various high-income countries and LMICs to improve patient care. The psychological impact of COVID-19 and associated lockdown measures, especially during the peak of COVID-19 waves, and the subsequent effect on the patient's mental health must also be considered in this high-priority group. We will continue to monitor the situation to provide direction in future pandemics.

Indexed as

breast cancerCOVID-19guidelineshealthcare managementhealthcare systemsurgerytreatmentunintended consequences

Identifiers

PMID36733464
PMCPMC9888303

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.